Citations

Mayo Clinic

Showing 10 of 108585 citations.

A CKD Patient with Microcystic Kidneys on Imaging
Bhasin, Bhavna , Koratala, Abhilash , Bhasin-Chhabra, Bhavna , Patel, Maitray D , Koratala, Abhilash , Patel, Maitray D.

Kidney360 | September 28, 2023 | Volume: 4 | Issue: 9 | Pages: e1343-e1344

10.34067/kid.0000000000000200 | PMID 37768812 Get It

Anesthetic management of parturients with achondroplasia: a case series
Dumitrascu, Catalina I. , Eneh, Peace, Keim, Audrey , Sharpe, Emily E. , Eneh, Peace Nnenna, Keim, Audrey Anne , Kraus, Molly B , Sharpe, Emily E , Kraus, Molly B.

Baylor University Medical Center Proceedings | September 28, 2023 | Volume: 37 | Issue: 1 | Pages: 63-68

10.1080/08998280.2023.2261084 | PMID 38173994 Get It

Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy
Coelho, Teresa , Dasgupta, Noel R., Parman, Yeşim , França, Marcondes C. , Guo, Yuh‐Cherng , Wixner, Jonas , Ro, Long‐Sun , Calandra, Cristian , Kowacs, Pedro André , Weiler, Markus , Jung, Shiangtung W., Büchele, Gustavo, Chen, Jersey , Hughes, Steven G. , Schneider, Eugene, Viney, Nicholas J. , Masri, Ahmad , Gertz, Morie R., Ando, Yukio, Khella, Sami, Dyck, P. James B. , Investigators, NEURO-TTRansform, Gane, Edward , Dávila, Lucía Galán, Mezei, Michelle M. , Moreno, Juan González, Cintas, Pascal , Traub, Rebecca , Khoury, Julie, Estol, Conrado J. , Polydefkis, Michael , Brannagan, Thomas H., Rugiero, Marcelo, Distad, B. Jane, Papanicolaou, Eleni Zamba, Lin, Kon‐Ping, Benson, Merrill D., Scheinberg, Morton , Gillmore, Julian D , Marques, Wilson , Chao, Chi‐Chao , Berk, John L. , Obici, Laura , Barroso, Fábio , Conceição, Isabel , Brambatti, Michela , Gertz, Morie A. , Ando, Yukio, Gillmore, Julian D. , Waddington‐Cruz, Márcia , Investigators, NEURO-TTRansform, Mazzeo, Anna Teresa , Papagianni, Aikaterini E. , Dimachkie, Mazen M. , Zaganas, Ioannis V. , Luigetti, Marco , Pareyson, Davide , Needham, Merrilee , Adams, David , Bril, Vera , Attarian, Shahram , Lin, Kon‐Ping

JAMA | September 28, 2023 | Volume: 330 | Issue: 15 | Pages: 1448

10.1001/jama.2023.18688 | PMID 37768671 Get It

Importance Transthyretin gene silencing is an emerging treatment strategy for hereditary transthyretin (ATTRv) amyloidosis. Objective To evaluate eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in ATTRv polyneuropathy. Design, Setting, and Participants NEURO-TTRansform was an open-label, single-group, phase 3 trial conducted at 40 sites across 15 countries (December 2019-April 2023) in 168 adults with Coutinho stage 1 or 2 ATTRv polyneuropathy, Neuropathy Impairment Score 10-130, and a documented TTR variant. Patients treated with placebo from NEURO-TTR ( NCT01737398 ; March 2013–November 2017), an inotersen trial with similar eligibility criteria and end points, served as a historical placebo (“placebo”) group. Interventions Subcutaneous eplontersen (45 mg every 4 weeks; n = 144); a small reference group received subcutaneous inotersen (300 mg weekly; n = 24); subcutaneous placebo weekly (in NEURO-TTR; n = 60). Main Outcomes and Measures Primary efficacy end points at week 65/66 were changes from baseline in serum transthyretin concentration, modified Neuropathy Impairment Score +7 (mNIS+7) composite score (scoring range, –22.3 to 346.3; higher scores indicate poorer function), and Norfolk Quality of Life Questionnaire–Diabetic Neuropathy (Norfolk QoL-DN) total score (scoring range, –4 to 136; higher scores indicate poorer quality of life). Analyses of efficacy end points were based on a mixed-effects model with repeated measures adjusted by propensity score weights. Results Among 144 eplontersen-treated patients (mean age, 53.0 years; 69% male), 136 (94.4%) completed week-66 follow-up; among 60 placebo patients (mean age, 59.5 years; 68% male), 52 (86.7%) completed week-66 follow-up. At week 65, adjusted mean percentage reduction in serum transthyretin was −81.7% with eplontersen and −11.2% with placebo (difference, −70.4% [95% CI, −75.2% to −65.7%]; P < .001). Adjusted mean change from baseline to week 66 was lower (better) with eplontersen vs placebo for mNIS+7 composite score (0.3 vs 25.1; difference, −24.8 [95% CI, −31.0 to −18.6; P < .001) and for Norfolk QoL-DN (−5.5 vs 14.2; difference, −19.7 [95% CI, −25.6 to −13.8]; P < .001). Adverse events by week 66 that led to study drug discontinuation occurred in 6 patients (4%) in the eplontersen group vs 2 (3%) in the placebo group. Through week 66, there were 2 deaths in the eplontersen group consistent with known disease-related sequelae (cardiac arrhythmia; intracerebral hemorrhage); there were no deaths in the placebo group. Conclusions and Relevance In patients with ATTRv polyneuropathy, the eplontersen treatment group demonstrated changes consistent with significantly lowered serum transthyretin concentration, less neuropathy impairment, and better quality of life compared with a historical placebo. Trial Registration ClinicalTrials.gov Identifier: NCT04136184 ; EU Clinical Trials Register: EudraCT 2019-001698-10
The utility of futility
Smoot, Rory L. , Nagorney, David M. , Smoot, Rory L

Hepatology | September 28, 2023 | Volume: 79 | Issue: 2 | Pages: 264-266

10.1097/hep.0000000000000614 | PMID 37768361 Get It

Evaluating skin colour diversity in the validation of scar assessment tools
Garg, Stuti P. , Williams, Tokoya, Taritsa, Iulianna C. , Wan, Rou , Goel, Chirag , Harris, Raiven, Huffman, Kristin, Galiano, Robert D. , Galiano, Robert D

Wound Repair and Regeneration | September 28, 2023 | Volume: 31 | Issue: 6 | Pages: 731-737

10.1111/wrr.13120 | PMID 37768279 Get It

Abstract Across scar studies, there is a lack of dark‐skinned individuals, who have a predisposition for keloid formation, altered pigmentation and poorer quality of life (QOL). There is a need for patients of colour to be included in scar scale development and validation. In this study, we evaluate the racial diversity of patients included in the validation of scar assessment scales. A systematic review was conducted for articles reporting on the validation of a scar assessment tool. Racial, ethnic and Fitzpatrick skin type (FST) data were extracted. Fifteen scar scale validation studies were included. Nine of the studies did not mention FST, race or ethnicity of the patients. Two of the studies that reported FST or race information only included White patients or included no FST V/VI patients: mapping assessment of scars (MAPS) and University of North Carolina ‘4P’. Only four studies included non‐White patients or dark‐skinned patients in the validation of their scar scale: the modified Vancouver Scar Scale (VSS), modified Patient and Observer Scar Assessment Scale (POSAS), acne QOL and SCAR‐Q scales. The patients included in the modified VSS validation were 7% and 13% FST V/VI, 14% African in the modified POSAS and 4.5% FST V/VI in the SCAR‐Q. We highlight the severe lack of diversity in scar scale validation, with only 4 out of 15 studies including dark‐skinned patients. Given the susceptibility of darker‐skinned individuals to have poorer scarring outcomes, it is critical to include patients of colour in the very assessment tools that determine their scar prognosis. Inclusion of patients of colour in scar scale development will improve scar assessment and clinical decision‐making.
Hourglass, a rapid analysis framework for heterogeneous bioimaging data, identifies sex disparity in IL‐6/STAT3‐associated immune phenotypes in pancreatic cancer
Aliar, Kazeera , Waterhouse, Henry R. , Vyas, Foram , Krebs, Niklas , Zhang, Bowen , Poulton, Emily , Chan, Nathan , González, Ricardo , Jang, Gun Ho , Bronsert, Peter , Gallinger, Steven , Grünwald, Barbara T , Khokha, Rama , Chan, Nathan , Gonzalez, Ricardo , Fischer, Sandra Elisabeth

The Journal of Pathology | September 28, 2023 | Volume: 261 | Issue: 4 | Pages: 413-426

10.1002/path.6199 | PMID 37768107 Get It

AbstractIntegration and mining of bioimaging data remains a challenge and lags behind the rapidly expanding digital pathology field. We introduce Hourglass, an open‐access analytical framework that streamlines biology‐driven visualization, interrogation, and statistical assessment of multiparametric datasets. Cognizant of tissue and clinical heterogeneity, Hourglass systematically organizes observations across spatial and global levels and within patient subgroups. Applied to an extensive bioimaging dataset, Hourglass promptly consolidated a breadth of known interleukin‐6 (IL‐6) functions via its downstream effector STAT3 and uncovered a so‐far unknown sexual dimorphism in the IL‐6/STAT3‐linked intratumoral T‐cell response in human pancreatic cancer. As an R package and cross‐platform application, Hourglass facilitates knowledge extraction from multi‐layered bioimaging datasets for users with or without computational proficiency and provides unique and widely accessible analytical means to harness insights hidden within heterogeneous tissues at the sample and patient level. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Disparities in care and outcomes for adolescent and young adult lymphoma patients
DuVall, Adam , Rosenthal, Allison , Duvall, Adam , Kahn, Justine M , Khan, Niloufer

eJHaem | September 28, 2023 | Volume: 4 | Issue: 4 | Pages: 934-939

10.1002/jha2.797 | PMID 38024615 Get It

AbstractThough survival outcomes among adolescents and young adults (AYAs) with lymphoma have improved over the last three decades, socially vulnerable populations including non‐White, low‐income, and publicly insured groups continue to trail behind on survival curves. These disparities, while likely the result of both biological and non‐biological factors, can be largely attributed to inequities in care over the full cancer continuum. Nationally representative studies have demonstrated that from diagnosis through therapy and into long‐term survivorship, socially vulnerable AYAs with lymphoma face barriers to care that impact their short and long‐term survival. Thus, improving outcomes for all AYAs with lymphoma requires dedicated study to understand, and then address the unique challenges faced by non‐White and low‐income lymphoma populations within this age group.
Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Welsh, Seth J. , Barwick, Benjamin G. , Meermeier, Erin W. , Riggs, Daniel L. , Shi, Chang-Xin , Zhu, Yuan Xiao , Sharik, Meaghen E. , Du, Megan T. , Rocha, Leslie D. Abrego , Garbitt, Victoria M. , Meurice, Nathalie , Alvarado, Yuliza Tafoya , Todd, Kennedi T. , Brown, Sochilt , Hammond, Zachery J., Cuc, Nicklus H. , Wittenberg, Courtney , Herzog, Camille , Roschke, Anna V. , Demchenko, Yulia N. , Chen, Wei-dong D. , Li, Peng , Liao, Wei , Leonard, Warren J. , Chesi, Marta , Bergsagel, P. Leif , Bergsagel, P. Leif , Abrego Rocha, Leslie D , Stein, Caleb K , Petit, Joachim L , Meurice, Nathalie , Tafoya Alvarado, Yuliza , Fonseca, Rodrigo , Todd, Kennedi T , Brown, Sochilt , Hammond, Zachery J , Cuc, Nicklus H , Wittenberg, Courtney , Herzog, Camille , Roschke, Anna V , Demchenko, Yulia N , Chen, Wei-Dong D , Li, Peng , Leonard, Warren J , Lonial, Sagar , Bahlis, Nizar Jacques , Neri, Paola , Boise, Lawrence H , Chesi, Marta , Barwick, Benjamin G , Riggs, Daniel L , Meermeier, Erin W , Stein, Caleb K. , Petit, Joachim L. , Fonseca, Rodrigo , Lonial, Sagar , Neri, Paola , Boise, Lawrence

Blood Cancer Discovery | September 28, 2023 | Volume: 5 | Issue: 1 | Pages: 34-55

10.1158/2643-3230.bcd-23-0062 | PMID 37767768 Get It

Abstract Multiple myeloma (MM) is a malignancy that is often driven by MYC and that is sustained by IRF4, which are upregulated by super-enhancers. IKZF1 and IKZF3 bind to super-enhancers and can be degraded using immunomodulatory imide drugs (IMiD). Successful IMiD responses downregulate MYC and IRF4; however, this fails in IMiD-resistant cells. MYC and IRF4 downregulation can also be achieved in IMiD-resistant tumors using inhibitors of BET and EP300 transcriptional coactivator proteins; however, in vivo these drugs have a narrow therapeutic window. By combining IMiDs with EP300 inhibition, we demonstrate greater downregulation of MYC and IRF4, synergistic killing of myeloma in vitro and in vivo, and an increased therapeutic window. Interestingly, this potent combination failed where MYC and IRF4 expression was maintained by high levels of the AP-1 factor BATF. Our results identify an effective drug combination and a previously unrecognized mechanism of IMiD resistance. Significance: These results highlight the dependence of MM on IKZF1-bound super-enhancers, which can be effectively targeted by a potent therapeutic combination pairing IMiD-mediated degradation of IKZF1 and IKZF3 with EP300 inhibition. They also identify AP-1 factors as an unrecognized mechanism of IMiD resistance in MM. See related article by Neri, Barwick, et al., p. 56. See related commentary by Yun and Cleveland, p. 5. This article is featured in Selected Articles from This Issue, p. 4
Novel Metabolites Are Associated With Thrombosis After Cardiac Surgery in Children With Congenital Heart Disease
Li, Shengxu , Watson, Dave , Jorgenson, Alissa , Adelekan, Zainab, Tang, Weihong , Garland, Kathleen, Zupancich, Leah, Dassenko, David, Edens, R. Erik, Overman, David M. , Huntley, Marnie T. , Tang, Weihong

Arteriosclerosis, Thrombosis, and Vascular Biology | September 28, 2023 | Volume: 43 | Issue: 11 | Pages: 2231-2239

10.1161/atvbaha.123.319181 | PMID 37767707 Get It

BACKGROUND: Thrombosis is a major complication after cardiac surgery in children with congenital heart disease. The mechanisms underlying thrombosis development remain poorly understood. We aimed to identify novel circulating metabolites before cardiac surgery that are associated with thrombosis after surgery in children with congenital heart disease. METHODS: In this prospective cohort study, all blood samples were drawn right before surgical incision and after the induction of anesthesia, and plasma was separated immediately under 4 °C. Untargeted metabolomic data were measured by Metabolon in plasma from children (age range, 0 days–18 years) with congenital heart disease undergoing cardiac surgery. The primary outcome was thrombosis within 30 days of surgery or before discharge. Associations of individual metabolites with thrombosis were assessed with logistic regression with false discovery rate correction for multiple comparison and adjustment for clinical characteristics; elastic net regression was used to select a prediction model. RESULTS: Out of 1115 metabolites measured in samples from 203 children, 776 met the quality control criteria. In total, 25 children (12.3%) developed thrombosis. Among the 776 metabolites, 175 were significantly associated with thrombosis (false discovery rate Q <0.05). The top 3 metabolites showing the strongest associations with thrombosis were eicosapentaenoate, stearidonate, and andro steroid monosulfate C 19 H 28 O 6 S (false discovery rate, 0.01 for all). Pathway analysis showed that the pathways of nicotinate and nicotinamide metabolism and glycerophospholipid metabolism were enriched (false discovery rate, 0.003 for both) and had significant impact on the development of thrombosis. In elastic net regression analysis, the area under the receiver operating-characteristic curve of a prediction model for thrombosis was 0.969 in the training sample (70% of the total sample) and 0.833 in the testing sample (the remaining 30%). CONCLUSIONS: We have identified promising novel metabolites and metabolic pathways associated with thrombosis. Future studies are warranted to confirm these findings and examine the mechanistic pathways to thrombosis.
Sirtuins: The NAD + -Dependent Multifaceted Modulators of Inflammation
Santos, Leonardo , Benítez-Rosendo, Andrés, Bresque, Mariana , Camacho-Pereira, Juliana , Calliari, Aldo , Escande, Carlos

Antioxidants & Redox Signaling | September 28, 2023 | Volume: 39 | Issue: 16-18 | Pages: 1185-1208

10.1089/ars.2023.0295 | PMID 37767625 Get It

Significance: Sirtuins are NAD + -dependent histone deacetylases regulating important processes in cellular biology such as inflammation, metabolism, oxidative stress, and apoptosis. Recent Advances: Despite initially being discovered to regulate transcription and life span via histone deacetylase activities, emerging data continually uncover new targets and propose additional roles. Due to the outstanding importance of the sirtuins in the control of the inflammatory response, their roles in the pathogenesis of several inflammatory-based diseases have become an area of intense research. Although sirtuins have been traditionally regarded as anti-inflammatory players, several recent findings suggest that their role in inflammation is complex and that in some cases sirtuins can indeed promote inflammation. Critical Issues: In this article, we provide an update on the latest findings concerning the new mechanisms of action and concepts about the role of sirtuins during inflammation. We focus on the impact that inflammatory-based processes exert on the liver, adipose tissue, and nervous system as well as on macrophage function and activation. Also, we discuss available data pointing to the dual role that, in particular contexts, sirtuins may have on inflammation control. Future Directions: Since the knowledge of sirtuin impact on metabolism is continually expanding, new venues of research arise. Besides become being regarded as candidates of therapeutic targets, posttranscriptional control of sirtuin expression by means of microRNAs challenges our traditional concepts of sirtuin regulation; importantly, the emerging role of NAD + metabolism in aging and longevity has added a new dimension to the interest in sirtuin function. Antioxid. Redox Signal. 39, 1185–1208.